Literature DB >> 2947537

Comparative study of cefoperazone and spectinomycin for treatment of uncomplicated gonorrhea in men.

E W Hook, F N Judson, M S Verdon, J M Ehret, H H Handsfield.   

Abstract

Beta-lactamase-negative Neisseria gonorrhoeae infections were treated with single-dose cefoperazone (0.5 or 1.0 g) or spectinomycin (2.0 g). Anogenital infections were cured in 36 (83%) of 43 volunteers given 0.5 g of cefoperazone, 61 of 61 volunteers given 1.0 g of cefoperazone, and 99 of 100 volunteers given spectinomycin. The cefoperazone geometric mean MIC for 242 isolates was 0.028 microgram/ml. Cefoperazone (1.0 g) and spectinomycin (2.0 g) are comparable for the therapy of anogenital gonorrhea in men.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2947537      PMCID: PMC176494          DOI: 10.1128/AAC.30.4.619

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  A community-based outbreak of infection with penicillin-resistant Neisseria gonorrhoeae not producing penicillinase (chromosomally mediated resistance).

Authors:  H Faruki; R N Kohmescher; W P McKinney; P F Sparling
Journal:  N Engl J Med       Date:  1985-09-05       Impact factor: 91.245

2.  In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains.

Authors:  C N Baker; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

3.  Treatment of uncomplicated gonorrhea in men with single-dose moxalactam.

Authors:  H H Handsfield
Journal:  Sex Transm Dis       Date:  1983 Oct-Dec       Impact factor: 2.830

4.  Cefoperazone for urethritis due to penicillinase-producing Neisseria gonorrhoeae.

Authors:  J H Kim; Y T Kim; D H Hwang
Journal:  Clin Ther       Date:  1984       Impact factor: 3.393

5.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

6.  In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.

Authors:  F W Heessen; H L Muytjens
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  Comparative study of ceftriaxone and spectinomycin in the treatment of uncomplicated gonorrhea in women.

Authors:  A C Collier; F N Judson; V L Murphy; L A Leach; C J Root; H H Handsfield
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

8.  Comparative study of ceftriaxone and spectinomycin for treatment of pharyngeal and anorectal gonorrhea.

Authors:  F N Judson; J M Ehret; H H Handsfield
Journal:  JAMA       Date:  1985-03-08       Impact factor: 56.272

9.  Detection of Chlamydia trachomatis inclusions in Mccoy cell cultures with fluorescein-conjugated monoclonal antibodies.

Authors:  W E Stamm; M Tam; M Koester; L Cles
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

10.  Treatment of uncomplicated gonorrhea with cefotaxime.

Authors:  H H Handsfield; K K Holmes
Journal:  Sex Transm Dis       Date:  1981 Jul-Sep       Impact factor: 2.830

View more
  1 in total

Review 1.  The use of cephalosporins for gonorrhea: the impending problem of resistance.

Authors:  Pennan M Barry; Jeffrey D Klausner
Journal:  Expert Opin Pharmacother       Date:  2009-03       Impact factor: 3.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.